Special Issue

Bioactive Compounds as Bacterial Efflux Pump Inhibitors

Message from the Guest Editors

Antibiotic resistance is responsible for approximately 700,000 yearly deaths worldwide. Therefore, managing infections caused by resistant bacteria and reducing the associated morbidity and mortality rates currently represent a significant challenge in public healthcare. Efflux pumps (EP) are cell membrane proteins that actively mediate the extrusion of dangerous compounds in various cells. In the context of antibiotic resistance, efflux pump expression stands out for the widespread occurrence among resistant bacterial strains, leading to the lack of effectiveness of a significant number of antibiotics. A large body of research has demonstrated that compounds of either synthetic or natural origin can potentiate the efficacy of conventional antibiotics against EP-overexpressing strains. Therefore, the discovery of bioactive compounds capable of acting as bacterial efflux pump inhibitors represents a promising strategy for combatting antibiotic resistance. Hence, we welcome research demonstrating the effectiveness of fully characterized bioactive compounds as efflux pump inhibitors and their impact on antibiotic resistance, through in vivo, ex vivo in vitro, and in silico testing.

Guest Editors

Prof. Dr. Jaime Ribeiro-Filho Oswaldo Cruz Foundation (FIOCRUZ), Eusébio, CE, Brazil

Dr. Irwin Rose Alencar Menezes

Department of Biological Chemistry, Universidade Regional do Cariri, Crato, Brazil

Deadline for manuscript submissions

closed (31 December 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/143627

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

